These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 27430109)
1. Association of vascular endothelial growth factor expression with patohistological parameters of cutaneous melanoma. Gacević M; Jović M; Zolotarevski L; Stanojević I; Novaković M; Miller K; Šuljagić V; Mijušković Ž; Vojvodić D Vojnosanit Pregl; 2016 May; 73(5):449-57. PubMed ID: 27430109 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi. Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459 [TBL] [Abstract][Full Text] [Related]
8. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma. Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299 [TBL] [Abstract][Full Text] [Related]
9. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of cytoplasmic p27 expression in human melanoma. Chen G; Cheng Y; Zhang Z; Martinka M; Li G Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2212-21. PubMed ID: 21828232 [TBL] [Abstract][Full Text] [Related]
11. Absence of estrogen receptors in dysplastic nevi and malignant melanoma. Lecavalier MA; From L; Gaid N J Am Acad Dermatol; 1990 Aug; 23(2 Pt 1):242-6. PubMed ID: 2212119 [TBL] [Abstract][Full Text] [Related]
12. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. Giatromanolaki A; Sivridis E; Kouskoukis C; Gatter KC; Harris AL; Koukourakis MI Melanoma Res; 2003 Oct; 13(5):493-501. PubMed ID: 14512791 [TBL] [Abstract][Full Text] [Related]
13. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas. Pisacane AM; Risio M Melanoma Res; 2005 Feb; 15(1):39-43. PubMed ID: 15714119 [TBL] [Abstract][Full Text] [Related]
14. Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma. Špirić Z; Eri Ž; Erić M Int J Surg Pathol; 2015 Dec; 23(8):629-37. PubMed ID: 25911567 [TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Salven P; Heikkilä P; Joensuu H Br J Cancer; 1997; 76(7):930-4. PubMed ID: 9328154 [TBL] [Abstract][Full Text] [Related]
16. [Expression and prognostic significance of galectin-1 and galectin-3 in benign nevi and melanomas]. Li ZW; Wang Y; Xue WC; Si L; Cui CL; Cao DF; Zhou LX; Guo J; Lu AP Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):801-5. PubMed ID: 24507096 [TBL] [Abstract][Full Text] [Related]
19. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Kaddu S; Smolle J; Zenahlik P; Hofmann-Wellenhof R; Kerl H Melanoma Res; 2002 Jun; 12(3):271-8. PubMed ID: 12140384 [TBL] [Abstract][Full Text] [Related]
20. The role of vascular endothelial growth factors and their receptors in malignant melanomas. Brychtova S; Bezdekova M; Brychta T; Tichy M Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]